Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine ... 332-239-2660 There is ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Myriad develops and offers genetic tests that help assess the risk of developing disease ... genetic insights can significantly improve patient care and lower healthcare costs. For more information, ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...